NAVIDEA BIOPHARMACEUTICALS, INC.
NAVB evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Lead Asset:
- tc99m tilmanocept (Phase 3)
What it means
What to watch
Prepared research question
What matters most for NAVB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
tc99m tilmanocept (Phase 3)
Next Catalyst
—
Tracking 1 pipeline candidate for NAVIDEA BIOPHARMACEUTICALS, INC..
Run NAVIDEA BIOPHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NAVIDEA BIOPHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is NAVIDEA BIOPHARMACEUTICALS, INC.'s lead drug candidate?
NAVIDEA BIOPHARMACEUTICALS, INC.'s most advanced tracked candidate is tc99m tilmanocept (Phase 3) for Rheumatoid arthritis (RA).
Who is the CEO of NAVIDEA BIOPHARMACEUTICALS, INC.?
Swing Foundation is the chief executive officer of NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB).
What therapeutic areas does NAVIDEA BIOPHARMACEUTICALS, INC. focus on?
NAVIDEA BIOPHARMACEUTICALS, INC. develops therapies across Oncology, Immunology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.